Testing a blood-monitor device during lung cancer immunotherapy
Part of Cancer, Immune system & allergy clinical trials.
This trial checks whether a device called TheraSure CNI-Monitor can be used while people with advanced lung cancer receive immunotherapy. It aims to improve monitoring during palliative (comfort-focused) treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign informed consent (and understand what the study involves).
- You are 18 years or older.
- You have non-small cell lung cancer that cannot be cured (stage III or IV) and is being treated for palliation.
- Your cancer treatment includes immunotherapy (using immunotherapy alone, in combination with another immunotherapy, or with chemotherapy).
- You are not currently taking part in another interventional clinical study.
- Your hemoglobin (Hb) is not below 9 g/dl.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how your body reacts to checkpoint inhibitors (immunotherapy drugs like Keytruda or Opdivo) for NSCLC. It involves blood tests to check for antibodies your immune system might make against the drug.
This study uses detailed “single-cell” testing to look for markers that can predict how well immunotherapy works and what side effects may happen. It is for people with non-small cell lung cancer starting standard first-line treatment.
This study checks whether tiny bits of tumor DNA in the blood can be measured over time in people with non-small cell lung cancer who are receiving immunotherapy. It aims to see if these blood tests can help track the cancer response or changes during treatment.
This study is looking at immune markers in people with advanced non-small cell lung cancer (NSCLC) that cannot be cured. It tests how well the immune system responds to treatment, and may help guide future care.
This trial uses a special blood test to look for tiny cancer DNA to estimate your risk of the cancer getting worse after first immunotherapy. It aims to help doctors monitor progression earlier and more accurately in advanced lung cancer.
This study is looking at a simple blood test to see if it can help track how well your immunotherapy is working. If you have advanced lung cancer and are getting a standard immunotherapy drug, you may be able to join.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.